NYSE:SLGN
SILGAN HOLDINGS INC
A global medical device innovator providing essential high-performance materials for surgical and diagnostic applications across major healthcare markets.
Key Metrics
Investment Thesis
Bull Case
Investors may view SILGAN as an attractive holding due to its dominant market position in specialized medical device materials with limited direct competition. The company's consistent generation of operating cash flow supports a robust shareholder return program through dividends and buybacks. Long-term growth potential exists in emerging therapeutic areas where the company is expanding its product portfolio.
Bear Case
The substantial long-term debt of $3.72B combined with high interest expenses poses a significant financial risk, especially if borrowing costs rise further. Recent revenue contraction from 2022 to 2024 suggests potential market headwinds that may persist or worsen in the near term. High levels of goodwill and accumulated other comprehensive losses indicate underlying asset valuation risks that could impact future earnings.
About SILGAN HOLDINGS INC
SILGAN Holdings Inc. is a global leader in medical devices, specializing in high-performance materials and solutions for healthcare applications. Operating primarily in the United States and Europe, the company provides critical components for surgical procedures, drug delivery systems, and diagnostic tools. Its diversified portfolio spans multiple therapeutic areas, including oncology, orthopedics, and cardiovascular care.
Analysis
Management Discussion
In 2025, SILGAN reported revenue of $6.48B and net income of $288.4M, showing resilience against prior year declines in 2023 and 2024. The company maintained a strong cash position with $1.08B in cash and equivalents while managing significant capital expenditures of $307.1M to sustain operations. Despite a high debt load of $3.72B, the operating cash flow of $729.8M provides ample liquidity for dividends, share repurchases, and strategic investments.
Industry Overview
The global medical device industry is characterized by rapid technological innovation and an increasing focus on minimally invasive procedures and personalized medicine. Companies must navigate complex regulatory environments and evolving reimbursement models while managing volatile raw material costs. Consolidation is common as larger players seek to acquire niche manufacturers to expand their product offerings.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $6.41B | $5.99B | $5.85B | $6.48B |
| Cost of Revenue | $5.36B | $5.00B | $4.84B | $5.33B |
| Gross Profit | $1.05B | $992.6M | $1.01B | $1.15B |
| Operating Expenses | $573.7M | $570.4M | $664.1M | $740.9M |
| Operating Income | $474.1M | $422.1M | $347.7M | $408.5M |
| G&A | $417.0M | $384.4M | $438.4M | $492.7M |
| Stock-Based Comp | — | — | — | $18.0M |
| D&A | $262.8M | $263.2M | $275.9M | $319.2M |
| Depreciation | $210.2M | $210.1M | $223.3M | $254.5M |
| Amortization | $52.6M | $53.1M | $52.6M | $64.6M |
| Other OpEx | $156.7M | $186.1M | $225.7M | $248.2M |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $126.3M | $173.3M | $166.4M | $189.4M |
| Pre-Tax Income | $474.1M | $422.1M | $347.7M | $408.5M |
| Income Tax | $133.3M | $96.2M | $72.0M | $123.3M |
| Continuing Ops | $340.8M | $326.0M | $275.7M | $285.2M |
| Discontinued Ops | $0 | $0 | $685.0K | $3.2M |
| Net Income | $340.8M | $326.0M | $276.4M | $288.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $340.8M | $326.0M | $276.4M | $288.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.13B | $2.35B | $2.52B | $2.99B |
| Cash & Equivalents | $585.6M | $642.9M | $822.9M | $1.08B |
| Accounts Receivable | $658.0M | $599.5M | $594.3M | $589.4M |
| Inventory | $769.4M | $940.8M | $928.1M | $1.08B |
| Prepaid Expenses | $119.7M | $165.7M | $177.5M | $241.7M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $5.21B | $5.26B | $6.06B | $6.41B |
| PP&E (Net) | $1.93B | $1.96B | $2.28B | $2.38B |
| Intangibles | $763.8M | $721.0M | $869.5M | $900.1M |
| Goodwill | $1.98B | $2.02B | $2.32B | $2.49B |
| Operating Leases | $205.8M | $223.9M | $206.1M | $255.6M |
| Other LT Assets | $327.0M | $337.5M | $387.5M | $384.5M |
| Total Assets | $7.35B | $7.61B | $8.58B | $9.40B |
| Current Liabilities | $1.44B | $2.31B | $2.25B | $2.45B |
| Current Debt | $80.1M | $880.3M | $716.9M | $631.6M |
| Current Leases | $41.8M | $45.9M | $48.9M | $50.7M |
| Other Current Liab | $1.03B | $1.13B | $1.17B | $1.32B |
| Long-Term Liabilities | $4.19B | $3.41B | $4.35B | $4.67B |
| Long-Term Debt | $3.35B | $2.55B | $3.42B | $3.72B |
| LT Operating Leases | $172.9M | $187.9M | $171.6M | $219.5M |
| Other LT Liab | $671.4M | $675.7M | $756.0M | $736.2M |
| Total Liabilities | $5.63B | $5.72B | $6.60B | $7.12B |
| Shareholders' Equity | $1.72B | $1.89B | $1.99B | $2.27B |
| Retained Earnings | $2.96B | $3.21B | $3.40B | $3.61B |
| AOCI | $-345.3M | $-251.4M | $-353.4M | $-213.6M |
| Treasury Stock | $1.24B | — | — | — |
| Total L&E | $7.35B | $7.61B | $8.58B | $9.40B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $340.8M | $326.0M | $276.4M | $288.4M |
| Non-Cash Adjustments | $524.9M | $5.8M | $583.4M | $185.9M |
| Working Capital Changes | $-117.4M | $150.8M | $-137.9M | $255.5M |
| Cash from Operations | $748.4M | $482.6M | $721.9M | $729.8M |
| Capital Expenditures | $215.8M | $226.8M | $262.8M | $307.1M |
| Cash from Investing | $-215.6M | $-223.8M | $-1.18B | $-297.3M |
| Debt Issuances | $6.0M | $12.3M | $983.6M | $703.6M |
| Debt Repayments | $301.3M | $58.1M | $100.0M | $725.2M |
| Share Buybacks | $45.1M | $184.0M | $9.3M | $74.9M |
| Dividends Paid | $71.9M | $78.9M | $82.1M | $85.8M |
| Cash from Financing | $-569.6M | $-211.4M | $662.5M | $-207.5M |
| FX Effect | $-9.0M | $9.9M | $-28.2M | $32.8M |
| Net Change in Cash | $-45.8M | $57.3M | $179.9M | $257.8M |
| Beginning Cash | $631.4M | $585.6M | $642.9M | $822.9M |
| Ending Cash | $585.6M | $642.9M | $822.9M | $1.08B |
Frequently Asked Questions
How does SILGAN HOLDINGS INC make money?
The company's revenue is driven by its core manufacturing of advanced polymer materials used in implantable devices and drug delivery systems. Key segments include surgical products for oncology and orthopedics, as well as diagnostic reagents and consumables for clinical laboratories. Additionally, SILGAN serves the cardiovascular market with specialized components that support complex interventional procedures.
What are the main risks for SLGN?
The medical device industry faces intense price pressure from payers and government programs, which could impact gross margins on high-volume items. Geopolitical instability or supply chain disruptions could affect the availability of raw materials needed for production. Regulatory changes in healthcare reimbursement policies may alter the demand landscape for specific therapeutic categories.
What is SLGN's competitive advantage?
SILGAN leverages proprietary material science to create custom medical devices with unique performance characteristics difficult to replicate by competitors. The company benefits from a global supply chain network that ensures consistent quality and rapid delivery for critical healthcare needs. Strong regulatory approvals in key markets like the US and EU provide long-term barriers to entry for new product entrants.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.